


2 June 2020
ASX Code: MXC

3,250 prescriptions milestone surpassed with rapid expansion of Mercury MGC Pharma product line

Key Highlights:

- MGC Pharma surpasses 3,250 prescriptions milestone, currently at 3,295, across existing geographies, a ~64% increase in prescriptions since January 2020
- A total of 1,338 patients have now been prescribed MGC Pharma products, a ~55% increase in patients since January 2020
- Strong sales growth achieved despite the outbreak of COVID-19 and impact on its European GMP manufacturing facilities and distribution networks
- Continued growth expected with MGC to expand its Mercury MGC Pharma product line of affordable CBD and THC products to include six additional products
- MGC Pharma well positioned with Mercury MGC Pharma for proposed TGA scheduling changes to allow low-dose Schedule 3 CBD medicines in Australian pharmacies by early 2021
- Strong pipeline for orders from distribution agreements in place for all products going into H2 2020

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce the Company is currently at 3,295 issued prescriptions of its standardised affordable cannabinoid medicines, across its existing markets of the UK, Australia, Brazil and Ireland.



The majority of the Company's prescribed products are CannEpil[®], MXP100 and MP100, under Special Access Schemes, with an average of 35% repeat patients receiving two or more additional prescriptions. MGC Pharma has issued a total of 50 prescriptions of CogniCann[®] to 23 patients, since first patient received medication on 20 January 2020.

These prescriptions and patient numbers do not include clinical trials numbers.

ASX
RELEASE

This represents a significant achievement for the Company as it has delivered higher than expected sales despite the outbreak of COVID-19 in recent months and the subsequent lockdown procedures within Europe for its manufacturing and distribution of its cannabinoid-based medicine products.

Expansion of Mercury MGC Pharma product line

As a result of the strong sales growth experienced to date, the Company will commence rolling out its expanded Mercury MGC Pharma product line to include six additional products with higher percentages of both CBD and THC, for distribution into existing markets. In addition to MP 100, the Mercury MGC Pharma range is to include;

- MP 200, a 200mg/ml CBD solution;
- MP 1:30, a 100mg/ml CBD and 3mg/ml THC solution;
- MP 1:1, a 25mg/ml CBD and 25mg/ml THC solution;
- MP 7:1, a 3.6mg/ml CBD and 25mg/ml THC solution;
- MP 15:1, a 1.7mg/ml CBD and 25mg/ml THC solution;
- MP 25, a 25mg/ml THC solution.



The Company has a strong pipeline of orders for its proprietary MP 100, CannEpil® and CogniCann® products and is confident the expansion of this product line will continue to deliver increasing sales opportunities for the Company. Additionally, the Company is focused on aggressively executing its sales and growth strategy for its expanded product line into existing and new geographies, with on-going evaluating and improving its current distribution channels. Following recent evaluations, the Company has terminated its MGC Pharma product distribution exclusivity agreement with GrowBiotech (UK) allowing the Company to access additional new sales and distribution opportunities within the U.K. market, which has recently started to grow significantly.

Well positioned for proposed TGA low dose CBD scheduling changes in Australia

A review of scheduling for low-dose CBD, to be considered at the Australian Therapeutic Goods Administration (TGA) Joint Advisory Committee on Medicines Scheduling meeting in June 2020, may result in some CBD medicines being reclassified to a lower, Schedule 3 classification. This would enable low-dose pharmaceutical-grade CBD to be purchased at pharmacies without a prescription by early 2021.

MGC Pharma is strongly positioned with its existing Mercury MGC Pharma line of products and established market presence in Australia, for the expected significant growth in demand for pharmaceutical CBD products from the proposed change to Schedule 3.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The Company is extremely pleased to have achieved the strong growth in both prescription and patient numbers in what has been a challenging operating environment due to the outbreak of COVID-19. The Company is responding to the current strong order pipeline and we look forward to further sales growth opportunities with the expansion of the Mercury MGC Pharma line of products.”

--Ends--

Authorised for release by the Board, for further information please contact:

PR/IR Advisors – Media & Capital Partners

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

Melissa.hamilton@mcpartners.com.au

Rod.Hinchcliffe@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    